Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Early initiation of prophylactic anticoagulation in COVID-19 patients newly admitted to hospital ...

Over the past 40 years, major changes have occurred in the area of anticoagulation management. New strategies have been developed for older anticoagulants, older beliefs have been challenged, new ...

Please provide your email address to receive an email when new articles are posted on . Anticoagulants are one of the most commonly prescribed medication classes, and the utilization of these agents ...

Pulmonary embolism (PE) remains a major cause of cardiovascular morbidity and mortality worldwide. It occurs when thrombotic material—most often ...

Blood thinners are often prescribed to prevent life-threatening clots. One type, called direct oral anticoagulants (DOACs), is used to treat a variety of conditions that affect blood vessels, the ...

Patients at high risk for thromboembolism who undergo aortic valve replacement with a mechanical valve can safely take less than the standard dose of warfarin after 3 months, according to results of ...

Please provide your email address to receive an email when new articles are posted on . In patients with atrial fibrillation with a stent planted at least 1 year prior, oral anticoagulation ...

Background: Patients taking oral anticoagulant therapy balance the risks of hemorrhage and thromboembolism. We sought to determine the association between anticoagulation intensity and the risk of ...

Our extensive research on the United States Anticoagulation Therapy (2024-2032) offers valuable insights for businesses. This comprehensive report delves into emerging trends, inv ...

For patients younger than 21 who have provoked venous thromboembolism (VTE), shortening the length of anticoagulation to prevent a recurrent event is no worse than using it for the standard 3 months, ...

Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...

BOSTON -- In deciding on anticoagulation with apixaban (Eliquis) for patients with device-detected, subclinical atrial fibrillation (SCAF), one key number appeared to distinguish those for whom the ...